Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $3.8 million.

  • Entrada Therapeutics' Depreciation & Amortization (CF) rose 33.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 22.36%. This contributed to the annual value of $3.8 million for FY2024, which is 33.76% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Depreciation & Amortization (CF) is $3.8 million, which was up 33.76% from $2.8 million recorded in FY2023.
  • Entrada Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $3.8 million during FY2024, with a 5-year trough of $326,000 in FY2020.
  • For the 3-year period, Entrada Therapeutics' Depreciation & Amortization (CF) averaged around $2.8 million, with its median value being $2.8 million (2023).
  • Data for Entrada Therapeutics' Depreciation & Amortization (CF) shows a peak YoY soared of 242.64% (in 2021) over the last 5 years.
  • Over the past 5 years, Entrada Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $326,000 in 2020, then surged by 242.64% to $1.1 million in 2021, then soared by 70.10% to $1.9 million in 2022, then skyrocketed by 49.53% to $2.8 million in 2023, then skyrocketed by 33.76% to $3.8 million in 2024.